Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Illumina, Inc.
The difficult investment environment has made it harder to build newcos, but panelists at the Galien Forum talked about how that might help limit some of the me-too companies that proliferate when financing is easier.
Carl Icahn has stepped up his attempts to take control of Illumina. This time the legendary corporate raider is demanding certain board members cover the costs of the failed Grail acquisition.
News We’re Watching: Illumina Looks At Grail Options, New AdvaMed Digital Health Division, Evolut FX Gets CE Mark
This week, Illumina responded to the European Commission’s order for it to divest Grail; StrokeDX won a global innovation competition; and the US Food and Drug Administration approved expanded labeling for Boston Scientific’s WaveWriter Alpha to include painful diabetic peripheral neuropathy.
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- GenoLogics Life Sciences Software
- GRAIL Inc.
- Verinata Health
- Illumina Ventures
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.